



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 7/01, 15/79, 15/62 A01N 63/00	A1	(11) International Publication Number: WO 93/25666 (43) International Publication Date: 23 December 1993 (23.12.93)
(21) International Application Number: PCT/AU93/00284 (22) International Filing Date: 15 June 1993 (15.06.93) (30) Priority data: PL 3039 16 June 1992 (16.06.92) AU PL 5913 19 November 1992 (19.11.92) AU (71) Applicant (for all designated States except US): COMMON-WEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION [AU/AU]; Limestone Avenue, Campbell, ACT 2602 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only) : DALL, David, James [AU/AU]; 3 Moncrieff Street, Dickson, ACT 2601 (AU). FERNON, Carol, Anne [AU/AU]; 18 Birrell Street, Page, ACT 2614 (AU). SRISKANTHA, Alagacone [LK/AU]; 31 MacCallum Circuit, Florey, ACT 2615 (AU).		(74) Agents: KILBORN, Paul, Anthony et al.; CSIRO, Head Office, Intellectual Property Group, 580 Church Street, Richmond, VIC 3121 (AU). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: RECOMBINANT ENTOMOPOXVIRUS (57) Abstract <p>Recombinant insect viruses, particularly recombinant <i>Heliothis armigera</i> entomopoxviruses (HaEPV) are described wherein heterologous DNA is located in non-essential regions of the viral genome. Such recombinant viruses are useful as biological insecticides and in the production of desired biologically-active proteins, polypeptides and peptides in cell-culture.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

RECOMBINANT ENTOMOPOXVIRUS

This invention relates to the production of recombinant entomopoxviruses (EPV's), particularly recombinant *Heliothis armigera* entomopoxviruses (HaEPV's), capable of expressing heterologous DNA sequences. Particular applications of the invention include the use of the recombinant entomopoxviruses as biological insecticides and in the production of desired, biologically-active proteins, polypeptides and peptides in cell culture.

Entomopoxviruses are large, double-stranded DNA viruses of insects, and have to date been described from species of caterpillars, beetles and locusts (Goodwin et al., 1991). The economic importance of these insect groups has led to serious consideration of EPV's as potential biological control agents, and investigation by others has documented various characteristics which support their use in this capacity. For example, while the collective EPV host range is broad, covering the important insect groups, individual EPV isolates generally have a narrow host range, allowing potentially high levels of control specificity. Additionally, vertebrates (and vertebrate cell cultures) exposed to large amounts of infectious EPV have shown no sign of infection or other discernible ill-effect (Buckner & Cunningham, 1972; Langridge, 1973).

These factors confer significant potential for the use of EPV's as insect control agents. Unfortunately however, most EPV's exhibit low levels of pathogenicity. This trait, which has prevented serious attempts to develop the viruses as major commercial insecticides, may be overcome, conceivably, by the production of recombinant entomopoxviruses capable of expressing heterologous DNA sequences encoding agents toxic or otherwise deleterious to insects.

Recombinant entomopoxviruses also hold great potential for the production of homogenous and biologically active proteins, polypeptides and peptides. Such products are presently generated either from recombinant bacteria or through the use of expression vectors in eukaryotic cells. The first method is technically more simple, but suffers from the drawback that many proteins of eukaryote origin are not correctly processed in bacteria. Without correct processing many proteins are biologically inactive, and thus of little use or value. On the other hand, production from expression vectors in vertebrate cells is traditionally more expensive, with smaller yields of protein. Some eukaryotic expression vectors (e.g. baculoviruses) also cause lysis of the host cell.

In contrast to the baculoviruses, EPV's do not necessarily cause lysis of the infected cell, thereby offering potential for long term persistent infection of large scale cell culture. This should permit enhanced production efficiency of proteins, especially of those which are secreted from the host cell, since collection of the product (via periodic removal of cell culture medium) will not require destruction of the cells.

Thus it is an object of the present invention to provide recombinant entomopoxviruses suitable for use as biological insecticides and/or as expression vectors for the production of desired proteins, polypeptides and peptides in cell culture systems. To achieve this object it is necessary that non-essential regions are identified in the genomes of EPV's. The identification of such regions would provide sites which could be utilised for development of an EPV viral vector, with heterologous DNA inserted into the non-essential region of the EPV genome by any of the methods known in the art (but most conveniently, homologous recombination), optionally with deletion of the non-essential region or portion thereof prior to insertion of the foreign DNA.

The spheroidin protein of EPV is a major component of the occlusion body (spheroid). Since occlusion is only required for horizontal virus transmission, and not infection, the single spheroidin gene driven by a strong promoter provides a very attractive site for the insertion of heterologous sequences into the EPV genome. The sequence of the gene which encodes *Amsacta moorei* EPV (AmEPV) spheroidin has now been reported (Hall and Moyer, 1991). Its product is a 115 kDa protein with a high cysteine content, and a large number of potential glycosylation sites. This protein is unrelated to others previously described, including the major protein component of purified preparations of *Choristoneura biennis* EPV (CbEPV), which has previously been identified as the spheroidin moiety of that virus (Yuen et al. 1990).

It has now been found that entomopoxviruses possess alternative, non-essential regions within their genomes which are suitable for use as sites for the introduction of heterologous DNA.

Accordingly, in one aspect of the present invention, there is provided a recombinant entomopoxvirus, characterised in that heterologous DNA is located in one or more of the following regions of the entomopoxvirus genome:

- (i) p11.5 open reading frame (ORF) region;
- (ii) thymidine kinase (TK) encoding region;
- (iii) spindle protein encoding region;
- (iv) an intergenic region.

By intergenic region it is meant any region of the viral genome which follows the first translation termination codon of an upstream gene or open reading frame (ORF) actually or potentially encoding a viral protein, and which precedes the translation initiation codon of the following downstream gene or ORF. As such the intergenic region may contain enhancer and

promoter elements, other functional elements, and other nucleotide sequences which lack identified activity.

Preferably, the heterologous DNA is inserted into the p11.5 ORF region or the spindle protein encoding region.

Preferably the recombinant entomopoxvirus is *Amsacta moorei* EPV, *Choristoneura biennis* EPV, *Heliothis armigera* EPV, *Choristoneura fumiferana* EPV, *Aphodius tasmaniae* EPV, *Dermolepida albohirtum* EPV, *Melolontha melolontha* EPV or *Servicesthis nigrolineata* EPV.

In addition to spheroids, many EPV isolates also produce large numbers of a second type of proteinaceous structure known as a spindle body. These bodies do not occlude virus particles and in some EPV's they are themselves occluded into the matrix of the spheroid. The spindle protein (fusolin) encoding region (and adjacent regions) have been isolated from *Heliothis armigera* EPV (HaEPV), and the sequence is provided at Figure 1. Thus, in a second aspect, the invention provides an isolated DNA molecule comprising the sequence for an EPV spindle protein or a portion thereof, optionally together with the 5' promoter sequence.

The p11.5 ORF and the adjacent 5' regions have also been isolated from HaEPV. The sequence of these regions is provided at Figure 1. Accordingly, in a third aspect, the invention provides an isolated DNA molecule comprising the sequence for p11.5 ORF or a portion thereof, optionally together with the 5' promoter/intergenic sequence.

In a further aspect, the invention provides a recombinant HaEPV, characterised in that heterologous DNA is located in one or more non-essential regions of the genome. Preferably, the heterologous DNA is inserted into one or more of the following regions of the entomopoxvirus genome:

- (i) p11.5 open reading frame (ORF) region;
- (ii) thymidine kinase (TK) encoding region;
- (iii) spindle protein encoding region;
- (iv) spheroidin encoding region;
- (v) an intergenic region.

More preferably, the heterologous DNA is inserted into the p11.5 ORF region or the spindle protein encoding region.

Recombinant entomopoxviruses according to the invention may be used as biological insecticides, optionally in admixture with an acceptable agricultural carrier. The heterologous DNA inserted into the genome of the recombinant EPV may comprise genes encoding one or more substances that are deleterious to insects. Such substances include, for example, *Bacillus thuringiensis* δ -toxin, insect neurohormones or proteins which interact with such hormones (e.g. juvenile hormone esterase), insecticidal compounds from wasp, scorpion venom or other heterologous origin, or factors designed to attack and kill infected cells in such a way as to cause pathogenesis in the infected tissue (e.g. a ribozyme targeted against an essential cellular function). Expression of the heterologous genes may be driven by the natural or other suitable promoter, but more preferably by an entomopoxvirus promoter, particularly the spindle protein gene promoter, the spheroidin gene promoter or the p11.5 ORF promoter. Thus, in a further aspect the present invention comprises an isolated DNA molecule comprising the promoter region, or a portion thereof, derived from the spheroidin gene or spindle protein gene of an entomopoxvirus or the p11.5 ORF of an insect virus, preferably an entomopoxvirus.

Further, the recombinant entomopoxviruses according to the invention may be used for the production of desired, biologically-active proteins, polypeptides or peptides, for example cytokines such as interferons (e.g. IFN- α , IFN- β , IFN- γ), tissue plasminogen activator (TPA), lymphotoxin

(LT), macrophage activating factor (MAF), insulin, epithelial cell growth factor (EGF), human growth hormone (hGH), antibodies and fragments thereof, etc. Expression of the gene encoding the desired product may be driven by the gene's natural promoter or another suitable promoter, but more preferably expression is driven by an entomopoxvirus promoter, particularly the spindle protein gene promoter, the spheroidin gene promoter or the p11.5 ORF promoter. Recombinant HaEPV's may be used to produce desired proteins, polypeptides and peptides by infecting cultured *Helicoverpa* or *Spodoptera* cells, for example, cells comprising or derived from the *Helicoverpa* BCIRL-HZ-AM1 line (U.S. Dept. of Agriculture), the *Spodoptera* Sf9 line (American Type Culture Collection), or similar cells.

The p11.5 ORF also appears to be both present and expressed in nuclear polyhedrosis viruses (NPV's). That is, GeneBank Accession M59422, locus NPAIEN, describes a 2011 bp ds-DNA from AcNPV which contains a previously undescribed ORF potentially encoding an HaEPV p11.5 homologue. The ORF is in reverse orientation, as published, beginning (i.e. 3' end of gene) at nucleotide position 1662. Using an AcNPV PCR-derived amplicon spanning positions 1662 to 1969 as template for a random primed labelled probe, Northern blots from AcNPV-infected and healthy *Spodoptera* Sf9 cells indicate that an RNA product of a size expected to encode the p11.5 protein homologue (about 300 nucleotides) is present in infected, but not healthy cells. This strongly suggests that the ORF is in fact a functional AcNPV gene. Expression of the AcNPV gene appears to peak about 48 hours post-infection.

Further, GeneBank Accession M63414, locus NPOIE1A, describes a 3792 bp ds-DNA sequence from *Orgia pseudotsugata* NPV (OpNPV) which also contains a previously undescribed ORF potentially encoding a p11.5 homologue. The region of homology extends from published base 350 (5' end of the

putative gene) to base 637, which is the last base of the putative translation termination codon.

Thus, in a still further aspect, the invention provides a recombinant NPV, characterised in that heterologous DNA is located in a region of the NPV genome substantially homologous to the p11.5 ORF entomopoxvirus region.

Preferably the NPV is a baculovirus, particularly AcNPV or OpNPV. The heterologous DNA may be of the kinds described above.

Thus, the invention should also be understood to extend to methods for producing desired proteins, polypeptides or peptides, comprising infecting susceptible host cells with a recombinant entomopoxvirus or recombinant nuclear polyhedrosis virus according to the present invention.

Recombinant HaEPV's may be used for the control of, for example, *Heliothis/Helicoverpa* species and *Spodoptera* species. Recombinant NPV's may be used for the control of, for example, various Lepidopterans. Thus, the invention also extends to methods for controlling the proliferation of pest insects, comprising applying to an infested area a recombinant entomopoxvirus or recombinant nuclear polyhedrosis virus according to the present invention, optionally in admixture with a suitable carrier.

As mentioned above, the heterologous DNA is most conveniently inserted into the non-essential region of the EPV or NPV genome by homologous recombination. Conceivably, homologous recombination may be achieved by using a construct wherein the heterologous DNA is flanked by a sequence of 5-10 nucleotide bases corresponding to the target, non-essential region. However, flanking sequences of 0.5-2.0 kb should provide desired recombinants with greater efficiency.

The invention will now be further described by way of the accompanying figures and the following non-limiting examples.

Brief Description of the Figures

- Figure 1 shows the genomic DNA sequence of *Heliothis armigera* entomopoxvirus p11.5 ORF, p50 spindle protein (fusolin), intergenic and flanking regions. The sequence is from the BglIII 4.9 Kb clone 36.
- Figure 2 compares the amino acid sequences of *Heliothis armigera* entomopoxvirus p50 spindle protein (top sequence) with the homologous protein from *Choristoneura biennis* entomopoxvirus (bottom sequence). Single letter amino acid code used throughout.
- Figure 3 compares the nucleotide sequence of the *Heliothis armigera* entomopoxvirus intergenic region between p11.5 ORF and p50 spindle protein (top sequence) with the nucleotide sequence immediately upstream of the homologous gene in *Choristoneura biennis* entomopoxvirus (bottom sequence).
- Figure 4 (A): Demonstration of GUS activity in *H. zea* cells infected with wild-type *Heliothis armigera* entomopoxvirus (HaEPV; left) or isolated G^+F^- recombinant HaEPV clone H12 (right).
- (B): Demonstration of GUS activity in *H. zea* cells infected with wild-type HaEPV (left) or G^+F^- recombinant HaEPVs derived from pEPAS3:GUS (right).

In each case it is clear that GUS activity is

absent in cells infected with wild-type HaEPV, but present in those infected with recombinant HaEPV.

Figure 5 provides a spectrophotometric analysis of lysates from cell cultures infected with GUS-expressing recombinant *Heliothis armigera* entomopoxvirus (HaEPV) clone H12 (solid line), wild-type HaEPV (dotted line) and mock-infected (dashed line). The absorption peak from GUS-expressing recombinant indicates the presence of GUS-catalysed reaction product.

Figure 6 Expression of the NC10 protein by recombinant *Heliothis armigera* entomopoxvirus (HaEPV). The figure shows a western blot of lysate of *H. zea* cells infected with a mixture of wild-type and NC10-expressing recombinant HaEPV's (lane 1), or with wild-type HaEPV only (lane 2). Arrow points to expected migration position of NC10 monomer in *H. zea* cell lysates; note presence of immunoreactive band at this position in lane 1, and failure to detect this band in lane 2. Numbers on left of figure show migration positions and molecular weights of protein markers.

Example 1: Characterisation of *Heliothis armigera* entomopoxvirus genes and viral proteins

Virus. Wild-type *Heliothis armigera* entomopoxvirus (HaEPV) was obtained from Dr. R.E. Teakle (Entomology Branch, Queensland Department of Primary Industries) and propagated in laboratory strains of *Helicoverpa armigera* derived from field collected insects (Fernon et al., in preparation).

Spheroids and associated spindle bodies were purified from macerated infected larvae by differential centrifugation. Purification of virions essentially followed the method of

Arif (1976); virions were released from spheroids by dissociation with sodium thioglycollate in carbonate buffer, centrifuged on 40-60% sucrose gradients in 1mM Tris pH 8.0 and dialysed against 2mM MOPS, pH 7.1.

Viral genomic DNA was purified from virions by incubation in 1 mg/ml protease K (room temperature overnight, then 2 h at 37°), extraction in TE-saturated (10 mM Tris, pH 8.0, 1 mM EDTA) phenol/chloroform/isoamyl alcohol (25:24:1 respectively), and precipitation.

Protein Analysis. HaEPV spheroids and spindle bodies were solubilised using the method described by Erlandson (1991), in the buffer described by Bilimoria and Arif (1979), except that final concentrations were 6.4M urea, 4% SDS and 4% mercaptoethanol. Proteins were separated by SDS-PAGE and stained with colloidal Coomassie Blue (Gradipore Australia). In some cases Laemmli gels were pre-run for 30 mins with 20 mM glutathione in the upper chamber running buffer; that buffer was discarded and replaced with standard running buffer prior to sample loading. Western blotting onto nitrocellulose membrane essentially followed the method of Towbin et al. (1979). Testing for glycosylation of denatured viral proteins blotted on nitrocellulose membrane employed a glycan detection kit (Boehringer Mannheim) used in accordance with manufacturer's instructions. Blotting of proteins onto PVDF membrane (Immobilon-P, Millipore) was by transfer at 250 mA for 1 h in 5 mM CAPS (cyclohexylamino-propanesulfonic acid), pH 10.5, with 10% methanol, in a BioRad MiniTrans-Blot Cell. After transfer the bands were visualised by staining and destaining in 0.1% Coomassie in 50% methanol, and 10% acetic acid in 50% methanol, respectively, and were then excised and washed thoroughly in sterile distilled water. N-terminal amino acid analysis of proteins on the PVDF matrix used an Applied Biosystems 477A pulsed liquid phase sequencer. The amino acid sequence data was subsequently used to validate the

identity of a sequenced ORF in a 4.9 kb BgIII HaEPV genomic DNA clone (#36).

Fusion protein and antiserum. A 972 bp SspI fragment, comprising most of the coding region of the p50 spindle protein (fusolin) gene, was excised by restriction digestion and cloned into the pGex3X expression vector (Glutagene; Smith & Johnson, 1988); the recombinant plasmid was grown in *E. coli* (strain TG-1). Expression of the HaEPV p50-glutathione-S-transferase fusion product was induced by addition of IPTG (1mM final concentration) to actively growing cells, and incubation for a further 3 h at 37°C. Bacteria were pelleted, resuspended in TEN (50 mM Tris, pH7.5; 2 mM EDTA; 100 mM NaCl) and lysed by incubation with lysozyme (0.2 mg/ml final concentration) for 30 min at 37°. Lysate was centrifuged (10000g, 5 min) and the pellet resuspended in PBS. The highly insoluble fusion protein was partially purified by incubation of the lysate at 60° for 30 min in the presence of 30 mM urea and 0.2% SDS. The lysate mixture was then centrifuged as above, the pellet resuspended in PBS, denatured by boiling in SDS-PAGE sample loading buffer (Sambrook et al. 1989) and the protein separated on SDS-PAGE gels (4% stacking; 12.5% resolving). The fusion protein band was excised from the polyacrylamide gel, and rerun on an agarose gel (ProSieve, FMC). Protein was then eluted from excised agarose band and concentrated by ultrafiltration.

Purified fusion protein (about 5µg) was mixed with Freund's adjuvant and injected subcutaneously into a rabbit. Booster injections used similar amounts of protein, and were administered 14, 28 and 35 days after the first injection; the latter boosters used the fusion protein in agarose gel matrix, thoroughly mixed with adjuvant. Antiserum was obtained from the rabbit on days 28 and 40.

For immunofluorescence studies suspensions of purified HaEPV spheroids and spindles were rinsed in PBS, washed twice in

0.05% Tween 20 in PBS, then incubated for 1 h at room temperature in 2% polyvinyl-pyrrolidone (PVP-40) in PBS. Preparations were washed twice more in 0.05% Tween 20, then incubated for 2 h in primary antibody (rabbit pre-immune serum, or anti-p50 fusion protein serum) diluted 1:500 in PBS. After washing three times, an equal volume of secondary antibody (FITC-conjugated goat and anti-rabbit IgG; Sigma F-9262) diluted 1:64 in PBS was added to the preparation and incubated overnight. The preparation was thoroughly rewashed in PBS, then mounted in 1% phenylenediamine in 50% glycerol in PBS. Examinations of fluorescence activity were made with a Wild Leitz confocal laser scanning microscope.

Proteins in HaEPV preparations. Electrophoresis of dissociated proteins from preparations containing HaEPV spheroids and spindles on Laemmli gels produced multiple bands of various intensities. When the same protein preparations were run on gels pre-treated with 20 mM glutathione, the profile was largely identical with the notable exception of a major band with apparent mobility of 50 kDa. Under standard Laemmli conditions a broad, diffuse band was observable in this region of the gel; with glutathione pre-treatment a sharply defined p50 band replaced the diffuse one, and under these conditions was the most abundant protein present in our preparations. Other major bands identified in the preparations have been designated p120, p98, p87 and p21 on the basis of their apparent molecular weights.

N-terminal amino acid analysis of blotted p50 gave a sequence of His-Gly-Tyr-Met-Thr-Phe-Pro-Ile-(Ile/Ala)-Ala-Gln for the first 11 residues. Attempts to define the N terminal amino acid composition of p120 by these methods were unsuccessful, apparently because the protein is blocked at that site.

Cloning and sequencing. Degenerate oligonucleotides were designed from the previously published sequence from *Chloristoneura biennis* EPV (Yuen et al. 1990) and

synthesised on a Pharmacia LKB Gene Assembler Plus; oligonucleotide sequences were (5') GAATATGC (A/T) GC (A/T) TTAGCAGG (A/T/C) CC, and (5') ACA (A/G) TT (A/G) TA (A/G) AA (T/A) CCTTC (T/A) CC (T/C) AC. These oligos were used with standard polymerase chain reaction techniques (Sambrook et al. 1989) to generate an amplicon from purified HaEPV genomic DNA. That reaction used a total of 31 cycles; initial template denaturation was for 5 min at 94°, then the first 5 cycles used annealing, extension and denaturation temperatures of 42°, 72° and 94° respectively, all for 1.5 min. Remaining cycles were identical except that the annealing temperature was 50°, denaturation time was 1 min, and in the last cycle the extension step was for 5 min. The amplicon from the reaction served as template for synthesis of a random primed ³²P-labelled DNA probe (Boehringer Mannheim). Southern blotting (Sambrook et al. 1989) was used to screen the fragments of interest in restriction enzyme digested HaEPV genomic DNA, and identified a 4.9 kb BglII fragment which was subsequently cloned into pTZ19R (Pharmacia).

This BglII fragment was subsequently cloned and sequenced (Figure 1). Within this fragment an open reading frame which included the N-terminal amino acid sequence of p50 was found. The open reading frame consists of 1056 bases (including the termination codon), and is predicted to encode a 351 amino acid protein with a molecular weight of 40132 Da, and an isoelectric point of 5.87. The amino acid sequence identified as forming the N-terminal portion of p50 (see above) begins at amino acid 21 of the predicted protein, and is identical to the predicted sequence at 10 of the 11 residues. (Nucleotide sequence data from three independent genomic clones of the gene clearly indicate that an Arg is the tenth amino acid of the mature form of p50). This finding indicates that p50 is post-translationally modified; the truncated mature form of the protein has a predicted molecular weight of 37730 Da, an isoelectric point of 5.63, and contains 9 cysteine residues.

The 20 amino acid peptide apparently cleaved during maturation of p50 has a predicted molecular weight of 2420, an isoelectric point of 8.07, and has an hydrophobic central core. These features are consistent with those found in other viral peptides which act as leader sequences, and which direct movement of nascent proteins across intracellular membranes.

Comparison of HaEPV p50 amino acid sequence with others available in the data bank revealed major homology only with the *Choristoneura biennis* EPV (CbEPV) 50K protein (Yuen et al. 1990) and a related 34.8K protein of *Autographa californica* NPV (Viallard et al. 1990). Individual alignment of HaEPV p50 with each of those proteins using the Gap algorithm showed 63 and 42% identities respectively. Comparison of the predicted full length amino acid sequence of HaEPV p50 with the CbEPV 50K protein is shown in Figure 2.

Each of the 9 cysteine residues in the mature form of HaEPV p50 has a corresponding Cys in CbEPV p50 (Yuen et al. 1990), and 6 of these 9 residues are also conserved in AcNPV p34.8. Conservation of the His-Gly-Tyr triad as the N-terminal end of the mature form of HaEPV p50 supports the previously suspected importance of this sequence (in combination with the amino acids immediately upstream) as a processing motif, and further suggests a likelihood of processing of AcNPV p34.8 at the analogous position (Viallard et al. 1990).

The 5' noncoding nucleotide sequence between the HaEPV p50 gene and the preceding putative open reading frame is 80 bases in length, 68 (85%) of which are A or T residues.

Comparison of the corresponding HaEPV and CbEPV noncoding regions using the Gap algorithm showed low (50%) nucleotide sequence homology (Figure 3).

Western blotting of proteins present in purified preparations of HaEPV (containing both spheroids and spindle bodies) shows that the spindle protein, p50, is by far the most abundant protein present. Experiments on viral proteins in infected cells suggest that the spindle protein is also highly abundant in that milieu. Assuming then that the spindle protein gene is present at only one copy per EPV genome (which all indications would lead us to expect), the promoter of the p50 gene would appear to be the most active HaEPV viral promoter.

HaEPV p50 fusion protein and serological assays. The fusion protein containing HaEPV p50 and glutathione-S-transferase (GST) sequences had an expected molecular weight of about 64 kDa. Under SDS-PAGE conditions in which GST ran at its expected apparent molecular weight, the fusion protein migrated with an apparent molecular weight of 81 kDa.

On Western blots, pre-immune serum did not recognise blotted HaEPV proteins, but anti-p50 fusion serum showed a complex staining pattern. In addition to the expected recognition of p50, the antiserum reacted strongly against p98, and also against several higher molecular weight bands. These observations strongly suggest that p98 is a dimer of p50, and it then also seems likely that the higher molecular weight bands recognised by the antiserum are higher-order multimers of p50. The antiserum did not recognise p120 which is believed to be HaEPV spheroidin.

The pre-immune serum showed only very low levels of staining when used in immunofluorescence studies with preparations of HaEPV. In contrast, the anti-p50 fusion serum specifically bound to HaEPV spindle bodies, but showed no reactivity to spheroids. Confocal laser scanning microscopy clearly showed localisation of the anti-p50 fusion antibody to the spindle body, as visualised by fluorescence from a labelled second antibody.

It has also been found that a gene homologous to that which encodes HaEPV p50 is present in an EPV of the Australian melolonthine scarab species *Sericesthis nigrolineata*. Spindle bodies are produced by this virus.

Genomic DNA of SnEPV was prepared by disruption of spheroid bodies in thioglycollic acid and carbonate buffer, addition of one-tenth volume of Tris buffer (10mM, pH 8.0) digestion with protease K (1 mg/ml, 4 hr at 37°), and dilution with 6 volumes of distilled water. A 4 microlitre aliquot of this preparation was used as template in a PCR amplification, using the protocol and oligonucleotides detailed earlier. An amplicon of about 500 bp produced in that reaction was purified and cloned into pTZ19U (Pharmacia). The cloned amplicon was sequenced, and analysis of results clearly indicated the existence of homology between the amplicon sequence and that of the HaEPV spindle protein gene.

PCR protocols have also been used to detect the presence of an HaEPV gene with homology to the *Amsacta moorei* EPV and *Choristoneura biennis* EPV (CbEPV) spheroidin gene (sensu Hall and Moyer, 1991, 1993). Oligonucleotides RM58 and RM118 (Hall and Moyer, 1993) were synthesised and used with the HaEPV genomic DNA preparation described earlier, in the manner already described. An amplicon of about 1.1 kb was produced in this reaction; this is very close in size to the amplicon reported to be produced when the same oligos are used with CbEPV DNA as template (Hall and Moyer, 1993), and together with the known specificity of the PCR process, this provides strong evidence that the HaEPV-derived amplicon represents a portion of a spheroidin gene homologue present in the HaEPV genome.

Given the correspondence between the HaEPV genome and those of other entomopoxvirus genomes, demonstrated by results of the various protocols described above, it is very likely that a similar PCR-based methodology could be used to identify the

presence of a thymidine kinase (TK) gene in the HaEPV genome. The presence of homologous TK genes in the genomes of AmEPV, CbEPV and *Choristoneura fumiferana* EPV has recently been demonstrated (Lytvyn et al. 1992).

Within the BglIII fragment, an open reading frame coding for a putative 11.5 kDa protein was also identified. Analysis of DNA sequence upstream of the p11.5 ORF suggests that it is likely to be a strong promoter suitable for the expression of heterologous sequences.

Example 2: Preparation of recombinant HaEPV

(i) G⁺F⁻ (i.e. GUS⁺ spindle protein (fusolin)⁻) HaEPV

Recombinant G⁺F⁻ HaEPV was prepared as follows:

The 4.9 kb BglIII HaEPV genomic fragment cloned in pTZ19R was used as the basis for construction of an EPV transfer vector. A section of that genomic fragment, approximately 700 bp in length, and delineated by the 5' BglIII site and an internal EcoRI site, was deleted, leaving about 4.2 kb of HaEPV genomic DNA which included the sequence presented in Figure 1. Site-directed mutagenesis was used to introduce a BamHI site between the upstream non-coding sequence and the coding region of the spindle protein gene. The transfer vector plasmid thus constructed was designated pEPAS3.

Further manipulation of pEPAS3 was achieved by use of a synthetic oligonucleotide (GATCTTAAATAGATCTATTTAA), which was self-annealed to give a dsDNA fragment with BamHI-compatible termini. This fragment was inserted into the BamHI site of pEPAS3, resulting in the incorporation of synthetic linker sequence, a vaccinia poxvirus consensus late promoter sequence (TAAAT), and a newly created BglIII site, into that transfer

vector. In the same process the pre-existing BamHI site of pEPAS3 was destroyed. This modified transfer vector was designated pEPAS3linker1.

The bacterial reported gene encoding the enzyme β -glucuronidase (GUS; Jefferson 1987) was inserted into the BglII site of pEPAS3linker1 to create pEPAS3linker1.GUS; in this construct an EcoRI site was introduced between the coding sequences of the GUS and spindle protein (fusolin) genes as a cloning artefact. The construct was multiplied in *E. coli* and subsequently purified by the Magic Maxiprep procedure (Promega). The purified DNA was transfected into *Heliothis zea* cells BCIRL-HZ-AM1 strain (McIntosh and Ignoffo, 1981) which had been infected by wild-type HaEPV 24 hours previously. Replication of HaEPV in these cells should be accompanied by the phenomenon of homologous recombination, resulting in the integration of a portion of the reporter (GUS)-containing construct into the genome of the virus. It was anticipated that the modified spindle protein promoter would drive expression of the GUS gene, and that the termination codon of the GUS gene would prevent co-expression of the spindle protein gene which was fused immediately downstream.

Medium harvested from the infected/transfected *Heliothis zea* cells described above contained infectious particles of HaEPV, and was used to initiate further infection of other *H. zea* cells. Serial dilution of this medium to levels at which only one infectious particle was present in a given volume of inoculum allowed isolation of a G^+F^- HaEPV recombinant, hereinafter designated as clone H12. Assessment of GUS activity of recombinant HaEPV's used the 5-bromo-4-chloro-3-indolyl glucurouide (X-GLU) substrate according to the protocol of Jefferson (1987b). Figure 4(A) shows the results of this assay in whole cell infected with wild-type HaEPV (left flask) or with the G^+F^- clone H12 HaEPV (right flask). It is clear that GUS activity is present only in the H12

HaEPV-infected cells. Figure 5 shows results of the enzymatic assay for GUS enzyme activity in lysates of cells infected with the G^+F^- clone H12 HaEPV, or wild-type HaEPV or mock-infected cells (i.e. no virus added) assessed by spectrophotometric analysis. It is clear that the GUS gene is expressed in the cells infected with the recombinant HaEPV, but that no such activity is associated with wild-type HaEPV, or the cells themselves.

A second recombinant G^+F^- HaEPV was prepared as described above, except that the GUS reporter gene was cloned into the BamH1 site of transfer vector pEPAS3 to give pEPAS3:GUS. This vector was transfected into H. zea cells infected by wild-type HaEPV 24 hours earlier, again in expectation that G^+F^- HaEPV recombinants with GUS gene expression driven by the wild-type spindle protein promoter, would be produced.

Assessment of GUS activity by the standard enzymatic assay again showed that the characteristic GUS-catalysed blue reaction product was present in cells subjected to the transfection/HaEPV infection protocol (Figure 4(B) right flask), but not in cells infected with wild-type HaEPV (Figure 4(B), left flask).

(ii) G^+i HaEPV

Recombinant HaEPV possessing a copy of the GUS encoding sequence at the intergenic region (i) between p11.5 ORF and the spindle protein gene was prepared as follows:

Once again, a plasmid transfer vector was prepared based on the cloned 4.9 kb BglIII HaEPV genomic segment.

Site-directed mutagenesis was used to introduce a BglIII site into the intergenic region between the p11.5 ORF and the spindle protein coding sequence, in a manner designed to retain full activity of the spindle protein promoter. In this

mutagenesis reaction the sequence ATATCT at positions -71 to -66 bases with respect to the spindle protein translation initiation codon (see Figure 1) was changed to AGATCT; the resultant transfer vector construct was designated pEPAS4.

A DraI-EcoRI fragment from the pEPAS3:GUS construct, consisting of 49 bases of the wild-type spindle protein promoter sequence and the GUS coding sequence, was excised, made blunt-ended with Klenow fragment DNA polymerase, and cloned into the end-filled intergenic BglII site of pEPAS4. The transfer vector thus constructed was designated pEPAS4:GUS.

(iii) Anti-neuraminidase⁺F⁻ HaEPV

A recombinant HaEPV was prepared which expresses fused elements of the variable domains of heavy and light immunoglobulin chains of a mouse antibody directed against the neuraminidase protein of an influenza virus. This expression product is of potential use for the *in vitro* diagnosis of influenza. That protein has been additionally engineered to contain an octapeptide sequence which is recognised by a commercially available monoclonal antibody (anti-FLAG MS2 antibody; International Biotechnologies).

The gene (Malby, R.L. et al., 1993) encoding that protein was cloned into the BaHI site of pEPAS3, to give the transfer vector pEPAS3:NC10. Cotransfection of H. zea cells was as described above. Expression of the gene by recombination was demonstrated by detection of the protein product, using the anti-FLAG MS2 monoclonal antibody in a Western blot of proteins from recHaEPV-infected cells (Figure 6).

(iv) est⁺F⁻ HaEPV

A recombinant HaEPV was prepared which expresses a juvenile hormone esterase gene of *Heliothis virescens* which has been mutated at position 201 to alter the serine residue to a glycine residue. This mutated protein has been shown to be highly insecticidal when expressed by a recombinant nuclear polyhedrosis virus and hence this recombinant HaEPV is considered to be a candidate for a useful viral insecticide.

This recombinant was prepared by cloning the mutated est gene into the BamHI site of pEPAS3 transfer vector, (Prof. B.B. Hammock, University of California, Davis, USA) and following the transfection/infection protocols described above.

References

- Arif, B.M. (1976). Isolation of an entomopoxvirus and characterisation of its DNA. *Virology* 69, 626-634.
- Bilimoria, S.L. & Arif, B.M. (1979). Subunit protein and alkaline protease of entomopoxvirus spheroids. *Virology* 96, 596-603.
- Buckner, C.H. & Cunningham, J.C. (1972). The effect of the poxvirus of the spruce budworm, *Choristoneura fumiferana* (Lepidoptera:Tortricidae), on mammals and birds. *Can. Ent.* 104, 1333-1342.
- Erlandson, M. (1991). Protease activity associated with occlusion body preparations of an entomopoxvirus from *Melanoplus sanguinipes*. *Journal of Invertebrate Pathology* 57, 255-263.
- Fernon, C.A. Vera, A.P., Crnov, R., Lai-Fook, J. & Dall, D.J. In vitro replication of *Heliothis armigera* EPV (in preparation).

Goodwin, R.H., Milner, R.J. & Beaton, C.D. (1991) Entomopoxvirinae. In Atlas of Invertebrate Viruses, Adams, J.R. & Bonami, J.R., eds. pp259-285. CRC Press, Boca Raton.

Hall, R.L. and Moyer, R.W. (1991) Identification, Cloning and Sequencing of a Fragment of Amsacta moorei Entomopoxvirus DNA Containing the Spheroidin Gene and Three Vaccinia Virus-Related Open Reading Frames. J. Virol. 65, 6516-6527.

Hall, R.L. and Moyer, R.W. (1993). Identification of an Amsacta spheroidin-like protein within the occlusion bodies of Choristoneura entomopoxviruses. Virology 192, 179-187.

Jefferson, R.A. (1987a) Plant Molecular Biology Reporter 5, 387-405.

Jefferson. R.A. (1987b). GUS Gene Fusion System User's Manual. Version 1.1 Cambridge, U.K.

Langridge, W.H.R. (1983). Detection of Amsacta moorei entomopoxvirus and vaccinia virus proteins in cell cultures restrictive for poxvirus multiplication. J. Invertebr. Pathol. 42, 77-82.

Lytvyn, V., Fortin, Y., Banville, M., Arif, B. and Richardson, C. (1992). Comparison of the thymidine kinase genes from three entomopoxviruses. J. Gen. Virol. 73, 3235-3240.

Malby, R.L., et al. PROTEINS: Structure, Function and Genetics, 16: 57-63, 1993.

McIntosh, A.H. and Ignoffo, C.M. (1981). Relication and infectivity of the single-embedded nuclear polyhedrosis virus, Baculovirus heliothis, in homologous cell lines. J. Invertebr. Pathol. 37, 258-264.

Sambrook, J. Fritsch, E.F. & Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual. Second Edition, Cold Spring Harbour Laboratory Press, New York.

Smith, D.B. & Johnson, K.S. (1988). Single step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione-S-transferase. Gene 67, 31-40.

Towbin, H., Staehelin, T. & Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, U.S.A. 76, 4350-4354.

Vailard, J.E., Yuen, L. & Richardson, C.D. (1990). Identification and characterisation of a baculovirus occlusion body glycoprotein which resembles spheroidin, and entomopoxvirus protein. J. Virol. 64, 5804-5811.

Yuen, L., Dionne, J., Arif, B. and Richardson, C. (1990). Identification and Sequencing of the Spheroidin Gene of *Choristoneura biennis* Entomopoxvirus. Virology 175, 427-433.

Other aspects of the present invention, and modifications and variations thereto, will become apparent to those skilled in the art on reading this specification, and all such other aspects and modifications and variations are to be considered as included within the scope of the present invention.

CLAIMS

1. A recombinant entomopoxvirus characterised in that heterologous DNA is located in one or more regions of the genome selected from the group comprising,
p11.5 open reading frame (ORF) region;
thymidine kinase (TK) encoding region;
spindle protein encoding region; and
an intergenic region.
2. A recombinant entomopoxvirus characterised in that heterologous DNA is located in the p11.5 ORF region of the genome.
3. A recombinant entomopoxvirus characterised in that heterologous DNA is located in the thymidine kinase (TK) encoding region of the genome.
4. A recombinant entomopoxvirus characterised in that heterologous DNA is located in the spindle protein encoding region of the genome.
5. A recombinant entomopoxvirus characterised in that heterologous DNA is located in an intergenic region of the genome.
6. A recombinant entomopoxvirus according to claim 5 wherein heterologous DNA is located in the intergenic region between p11.5 ORF and the spindle protein encoding region.
7. A recombinant entomopoxvirus according to any one of the preceding claims wherein the entomopoxvirus is *Amsacta moorei* EPV, *Choristoneura biennis* EPV, *Heliothis armigera* EPV, *Choristoneura fumiferana* EPV, *Aphodius tasmaniae* EPV, *Dermolepida*

albohirtum EPV, *Melolontha melolontha* EPV or *Servicesthis nigrolineata* EPV.

8. A recombinant *Heliothis armigera* entomopoxvirus (HaEPV) characterised in that heterologous DNA is located in one or more non-essential regions of the genome.
9. A recombinant HaEPV characterised in that heterologous DNA is located in one or more regions of the genome selected from the group comprising:
 - p11.5 open reading frame (ORF) region;
 - thymidine kinase (TK) encoding region;
 - spindle protein encoding region;
 - spheroidin encoding region; and
 - an intergenic region.
10. A recombinant HaEPV characterised in that heterologous DNA is located in the p11.5 ORF region of the genome.
11. A recombinant HaEPV characterised in that heterologous DNA is located in the thymidine kinase (TK) encoding region of the genome.
12. A recombinant HaEPV characterised in that heterologous DNA is located in the spindle protein encoding region of the genome.
13. A recombinant HaEPV characterised in that heterologous DNA is located in the spheroidin encoding region of the genome.
14. A recombinant HaEPV characterised in that heterologous DNA is located in an intergenic region of the genome.
15. A recombinant HaEPV entomopoxvirus according to claim 14 wherein heterologous DNA is located in the

intergenic region between p11.5 ORF and the spindle protein encoding region.

16. A recombinant nuclear polyhedrosis virus (NPV) characterised in that heterologous DNA is located in a region of the genome substantially homologous to at least a portion of the p11.5 ORF entomopoxvirus region.
17. A recombinant NPV according to claim 16 wherein the NPV is a baculovirus.
18. A recombinant NPV according to claim 17 wherein the NPV is AcNPV or OpNPV.
19. A recombinant virus according to any one of the preceding claims wherein the heterologous DNA comprises at least one gene encoding a substance deleterious to insects.
20. A recombinant virus according to claim 19 wherein the heterologous DNA encodes a substance selected from the group comprising: *Bacillus thuringiensis* δ -toxin; insect neurohormones; proteins which interact with insect hormones; insecticidal compounds from wasp, scorpion venom or other heterologous origin; or a ribozyme targeted against an essential insect cellular function.
21. A recombinant virus according to claim 19 wherein the heterologous DNA encodes juvenile hormone esterase.
22. A recombinant virus according to any one of claims 1-18 wherein the heterologous DNA comprises at least one gene encoding a desired biologically-active protein, polypeptide or peptide.

23. A recombinant virus according to claim 22 wherein the heterologous DNA encodes a substance selected from the group comprising; IFN- α , IFN- β , IFN- δ , TPA, lymphotoxin, macrophage activating factor, insulin, epithelial cell growth factor, human growth factor, antibodies and antibody fragments.
24. A recombinant virus according to claim 22 wherein the heterologous DNA encodes fused elements of the variable domains of murine heavy and light immunoglobulin chains directed against neuraminidase of influenza virus.
25. A recombinant virus according to any one of claims 19-24 wherein expression of the heterologous DNA is driven by an entomopoxvirus promoter.
26. A recombinant virus according to claim 25 wherein the entomopoxvirus promoter is the spindle protein promoter, spheroidin promoter or p11.5 ORF promoter from *Heliothis armigera* EPV.
27. A method for controlling the proliferation of pest insects, comprising applying to an infested area a recombinant virus according to any one of claims 19-21, 25 or 26 optionally in admixture with an acceptable agricultural carrier.
28. A method for producing a desired protein, polypeptide or peptide comprising infecting susceptible host cells with a recombinant virus according to any one of claims 22-26.
29. A recombinant virus according to any one of claims 1-26 wherein the heterologous DNA is located in the viral genome via homologous recombination.

30. An isolated DNA molecule comprising a nucleotide sequence encoding *Heliothis armigera* entomopoxvirus spindle protein or a portion thereof.
31. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to nucleotide 443 to nucleotide 1498 in Figure 1.
32. An isolated DNA molecule comprising a nucleotide sequence encoding p11.5 ORF or a portion thereof.
33. An isolated DNA molecule comprising a nucleotide sequence encoding *Heliothis armigera* p11.5 ORF or a portion thereof.
34. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to nucleotide 57 to nucleotide 362 Figure 1.
35. An isolated DNA molecule comprising a nucleotide sequence encoding the intergenic region, or a portion thereof, that lies between p11.5 ORF and the spindle protein encoding region of an entomopoxvirus genome.
36. An isolated DNA molecule comprising a nucleotide sequence encoding the intergenic region, or a portion thereof, that lies between p11.5 ORF and the spindle protein encoding region of *Heliothis armigera* entomopoxvirus genome.
37. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to nucleotide 363 to nucleotide 442 Figure 1.
38. An isolated DNA molecule comprising a nucleotide sequence encoding an entomopoxvirus promoter or functional portion thereof.

39. An isolated DNA molecule according to claim 38 wherein the promoter is the spindle protein promoter.
40. An isolated DNA molecule according to claim 39 wherein the spindle protein promoter is derived from *Heliothis armigera* entomopoxvirus.
41. An isolated DNA molecule according to claim 38 wherein the promoter is the p11.5 ORF promoter.
42. An isolated DNA molecule according to claim 41 wherein the p11.5 ORF promoter is derived from *Heliothis armigera* entomopoxvirus.
43. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to nucleotide 1 to nucleotide 56 in Figure 1.
44. An isolated DNA molecule encoding a fused promoter element comprising an entomopoxvirus spindle protein promoter sequence and a vaccinia consensus late promoter sequence.
45. A recombinant virus substantially as hereindescribed with reference to Example 2.

FIGURE 1

1 60
TAATACTCAGTTAAATGCAATGTTTGAATTTTATTAATAAAATTAATAAATGA
-----+
M I
Start p11.5 ORF

61 120
TTATATGCTATAAATTATGCAATTATTAATTGTATAATTAATAAAGTCTA
-----+
I C Y I I Y A I I I I C I I L I K S T

121 180
CAAAATAAATCAAGATAACCACTCCCGATCCAGAAAATGTCTCCTCCGGGAG
-----+
K I N Q D N H T P D P E N E I C P P G V

181 240
TATTGGTAATATACCACATCCATATTAATTGCAATAGATTTTATCTTTGCGCCCGCGAA
-----+
F G N I P H P Y Y C N R F Y L C A A G N

241 300
ATCGGATATTACTATTCTGTGCTGAAGGTCAATGAATATGATCCTACAATTAGAATGCG
-----+
A I L L F C A E G H E Y D P T I R T C V

FIGURE 1 continued

360
TATTAATATCCGAATATGGATGTACGGCAACCAAAATAGAAAAAAGTAAAGAAAT
-----+-----+-----+-----+-----+-----+
L I S E Y G C T A N Q N R K K S K R K *
End p11.5 ORF

361
AATTATTAATTATCTATGAAAAATAAGTTTAAATAATCAAAATAACGAAATAAACCA
--
| Start intergenic region

480
AAATACAAACCAAGATTAATAATGAATAAATCTATTATATATGTATTATATCAATAT
-----+-----+-----+-----+-----+-----+
M N K F Y Y I C I Y I N I
end intergenic region | Start p50 spindle body protein

540
TTTATACGTCGCTTAGCGGCATGGATATATGACATTTCTCTATAGCCAGGCAGAGAAG
-----+-----+-----+-----+-----+-----+
L Y V C V S G H G Y M T F P I A R Q R R

600
ATGTTGGTAAGGGAGGTCAGTGGTGCCACCCTAACGGAGATGGAATACTGATACTAT
-----+-----+-----+-----+-----+-----+
C S V R G G Q W W P P N G D G I T D T M

FIGURE 1 continued

660
GTGTAGGCGCGCTTATCAAAATGTATATAATAAAGTATTAAATCAATATAATGACCCACA
-----+-----+-----+-----+-----+-----+
C R A A Y Q N V Y N K V L N Q Y N D P Q

661
720
AGAGGCTGCTACTGCTGCTCAATATATGTTCACAGGATAATGAATATGCTGCCCTTGGC
-----+-----+-----+-----+-----+-----+
E A A T A A Q Y M F Q Q D N E Y A A L A

780
AGGACCGATTATACATAATTATGTAAATTGCAACAAATGTAGTACCTAACAATTATG
-----+-----+-----+-----+-----+-----+
G P D Y T N L C N L Q Q N V V P N N L C

781
840
CGCCGGGAGCCGATGATTGGGATGTAGTTCCATTCCGGAGATAAGAGTGGAAATGGATT
-----+-----+-----+-----+-----+-----+
A A G A D D W D V V P F G D K S G M D L

841
900
GCCAGGAAATTGGGTACCTACCGTTATTCCCTTGTATAGCAACCACCAATCTAGCGTAGC
-----+-----+-----+-----+-----+-----+
P G N W V P T V I P L D S N H Q S S V A

FIGURE 1 continued

960
TCTAGAATTGGAATTTGTCCCTACTGCTGTTCAATGATCCTAGCTATTATGAAGTTTATAT
-----+-----+-----+-----+-----+-----+
L E L E F C P T A V H D P S Y Y E V Y I
961
CACTAATTCGGGATTTAATGTACATACCGATAATGTAGTATGGGGTAACCTAGAATTGAT
-----+-----+-----+-----+-----+-----+
T N S G F N V H T D N V V W G N L E L I
1020
ATTTAATGATACAGTTCATTAAAGACCCAAATCTAGTACTTCGACTTGTAATGCTAATCC
-----+-----+-----+-----+-----+-----+
F N D T V P L R P K S S T S T C N A N P
1080
AAACGTTTATAGATTTACAGTATCTATTCCCGTAAGACCTGCTCAATTGTATTATATGT
-----+-----+-----+-----+-----+-----+
N V Y R F T V S I P V R P A Q F V L Y V
1140
AAGATGGCAAAGAATCGATCCCGTCGGTGAAGGATTTTATAATTGTGTGACATGGCATT
-----+-----+-----+-----+-----+-----+
R W Q R I D P V G E G F Y N C V D M A F
1200

FIGURE 1 continued

1201 1260
CGATTATGCTGCCGACCTTCCGAAGAAGATGTAATATATCCAGATTACGAGGCTCCTGG
-----+-----+-----+-----+-----+-----+
D Y A A G P S E E D V I Y P D Y E A P G

1261 1320
ACAGAATGCATACACTTGTCTATGCTAATAGAAATAATACGGAGGAAATTATGAAAATAC
-----+-----+-----+-----+-----+-----+
Q N A Y T C H A N R N K Y G G N Y E N T

1321 1380
TATCGATGAAGATAAATATCAGGCTCAGTTAGATGAATCTATAAGAGTAGATACGACAA
-----+-----+-----+-----+-----+-----+
I D E D K Y Q A Q L D E S I K S R Y D K

1381 1440
ATATAGTAGACATAAAGGAGGAAATTCGGACAAACAATGTAAATGGTAATAAACACCA
-----+-----+-----+-----+-----+-----+
Y S R H K G G K F G Q K Q C N G N K H H

1441 1500
TTATAATAATATACCAAATATTATAACCAAATTTATAAAAATAACAAAATTATTAAATT
-----+-----+-----+-----+-----+-----+
Y N K Y T K Y Y N Q N Y K N N K N Y *
end p50 spindle body protein

1501 1560
TCGGGAGTATGGATTATAATACGATCGATAGACACGAGCCCAATGATTATTACCAAAGATA

FIGURE 2

MNKFYYICIIYINILYVCVSGHGYMTFFIARQRRCSVRGGQWWPPNGDGIT
|||:::||::||::|||::|||::|||::|||::|||::|||::|||::|||:
MNKLILISLIASLYQVEVDAGHYMTFFIARQRRCSAAGNWNYPVGGGIQ

**DTMCRAAYQNVYNKVLNQY.NDPQEAAATAAQYMFQQDNEYAALAGPDYTN
|.|||||:|||||.:.|||.:||:|||||
DPMCRAAYQNVFNKVLNSGGDVIDASEAANYMYTQDNEYAALAGPDYTN**

L
C
N
L
Q
Q
V
P
N
N
L
C
A
G
A
D
D
W
D
V
P
F
G
K
S
G
M
D
L
P
G
N
W
V
T
V
I
P
L
D
S
N
H
Q

:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:

I
C
H
I
Q
R
V
P
S
Y
L
C
A
G
A
S
D
W
S
I
R
P
F
G
K
S
G
M
D
L
P
G
S
W
T
P
T
I
I
Q
L
S
D
N
Q
Q

SSVALELEFCPTAVHDPSEYEVYITNSGFNVHTDNVVGWGNLELIFNDTVP
|.|.:.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.|.
SNVVMELEFCPTAVHDPSEYEVYITNPSFNVTDNVVGWANLDLIYNNTVT

FIGURE 2 continued

**L L R P K S S T S T C N A N P N V Y F T V S I P V R P A Q F V L Y V R W Q R I D P V G E G F Y N C V
| | | | . . | | | . | | | . | | | . | | | . | | | . | | | .
L L R P K L P E S T C A N S M V Y R F F E V S I P V R P S Q F V L Y V R W Q R I D P V G E G F Y N C V**

DMAFDYAAGPSEEDVIYPDYEAPGQNAYTCHANRNKYGNGYENTIDEDKY
|||. . ||| : || | : | | | . . | | | . : : | :
DMKF KYSEGPD E D I IEPEYE . VDN EAECFA YRTNSGNVNVNPL QENKY

QAQLDESIKSRYDKYSRHKGGKFGQKQCNGNKHYYNKYTKYYNQNYKNNK
MAYANKAIR...NINTHSNG...CSRNRNKNKNYKYSKTYNYNQ

NY*

NRK*

FIGURE 3

...TTATTAAATTATCTATGAAAAATAAGTTTAAAAAAT
| | | | | | | | | | | | | | | | | | | |
AATACCAATATTTTACTACAACTCTAAATAAAAAATAGAAATAAT

CAAAATAACGAAATAAACCAAAATACAAACCAAGATTAAATA
| | | | | | | | | | | | | | | | | | | |
TTATTATTATAAATAAGCAAAAAATAAAAAACAAATA...:

FIGURE 4(A)




FIGURE 4(B)






FIGURE 5



SCAN SPEED: 120.0 nm/min
BANDPASS: 1.00nm


FIGURE 6



INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 93/00284

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁵ C12N 7/01, 15/79, 15/62, A01N 63/00 According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC ⁵ C12N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU IPC ⁵ C12N 7/01, 15/79 Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) WPAT KEYWORDS-ENTOMOPOXVIRUS, POLYHEDROSISVIRUS, POLYHEDROSIS (W) VIRUS, HETEROLOG BIOT KEYWORDS-POLYHEDROSIS VIRUS, POLYHEROSIS (W) VIRUS, HETEROLOG, EPV, NPV. CASM KEYWORDS-ENTOMOPOXVIRUS, POLYHEDROSISVIRUS, POLYHEDROSIS (W) VIRUS, HETEROLOG, EPV, NPV.					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.			
X	AU,A, 37516/91 (THE TEXAS A & M UNIVERSITY SYSTEM) 2 April 1992 (02.04.92)	1-45			
P,X	AU,A, 16634/92 (UNIVERSITY OF FLORIDA) 3 September 1992 (03.09.92)	1-45			
Y	AU,A, 82133/91 (SMITHKLINE BEECHAM CORPORATION) 9 January 1992 (09.01.92)	1-45			
Y	JOURNAL OF GENERAL VIROLOGY (1990), 71,1525-1534 published 1990	1-45			
<div style="display: flex; justify-content: space-between; align-items: flex-start;"> <div style="width: 45%;"> <input type="checkbox"/> Further documents are listed in the continuation of Box C. </div> <div style="width: 45%;"> <input type="checkbox"/> See patent family annex. </div> </div>					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;"> * Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 33%; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> <td style="width: 33%;"></td> </tr> </table>			* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the international search 2 September 1993 (02.09.93)		Date of mailing of the international search report 13 SEP 1993 (13.09.93)			
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. 06 2853929		Authorized officer <div style="text-align: center;">  J.W. ASHMAN Telephone No. (06) 2832364 </div>			

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
A	AU,A, 86550/91 (THE TEXAS A & M UNIVERSITY SYSTEM) 2 April 1992 (02.04.92)	
A	AU,A, 54780/90 (YUEN K L et al.) 15 November 1990 (15.11.90)	